Abstract: Processes for recovering colloids of carboxylate ligand modified ferric iron hydroxide materials such as IHAT (Iron Hydroxide Adipate Tartrate) are described based on the use of water miscible non-aqueous solvents, such as ethanol, methanol and acetone. The processes produce materials with advantageous properties such as improved bioavailability, reduced aggregation and/or agglomeration and/or increased iron content.

Abstract: Provided is a composition, in particular a solid pharmaceutical composition comprising a compound having the formula I as a free base or a salt thereof, and a mixture comprising a vehicle and a non-ionic surfactant in an amount sufficient to achieve solubilization of compound (I), wherein typically the composition is coated with an enteric coating and its use in the treatment of cancer.

Abstract: Disclosed herein are novel drug carriers including a non-aqueous pH dependent release system and a non-aqueous pH dependent reassembly/assembly and reabsorption/absorption system. The carriers are capable of pH dependent release of biologically active agents and assembly or reassembly when the carrier transitions from a low pH environment, to a high pH environment and back to a low pH environment.

Abstract: Methods, systems, and kits are provided for in situ seed treatment with liquid crop benefit compositions at planting in furrow.

Abstract: The present invention relates to a composition for surface modification. The composition for surface modification according to the present invention contains a particular carbodiimide-based compound, thus forms a covalent bond without damaging skin, hair, or fabric, and semipermanently provides desired skin or hair surface modification effects or fabric care effects.

Abstract: The present invention provides stabilized amorphous calcium carbonate (ACC) formulations, comprising ACC and a non-aqueous liquid carrier in which the ACC is dispersed. The present invention further provides cosmetic and pharmaceutical compositions comprising ACC.

Abstract: Provided herein are the long-acting injection compositions of ?3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes.

Abstract: This invention relates to clear one-phase liquid formulation vehicles comprising lecithin, MCT, bile salt and water.

Abstract: A method for forming crystalline solid dispersions (CSDs) of a pharmaceutical agent with low water solubility is described. The properties of the CSDs are described. Also described is the enhancement of bioavailability of the pharmaceutical agent resulting from formation of the CSD.

Abstract: The present invention relates to injectable, thermosensitive hydrogel compositions comprising linezolid for relieving and/or treating chronic low back pain (CLBP).

Abstract: This invention relates to methods comprising administering a FAK inhibitor (e.g., VS-6063) in combination with a dual RAF/MEK inhibitor (e.g., CHS 126766) that are useful in the treatment of abnormal cell growth, such as cancer, in a subject such as humans.

Abstract: Provided herein is a novel composition for oral administration and delivery of Noble gas, such as xenon or argon. Methods of treating and preventing neuronal or cardiovascular damage with such compositions are also provided.

Abstract: Formulations containing pH-sensitive nanoparticles for the enteric delivery of therapeutic agents are provided. The nanoparticles include a pH-sensitive polymer that protects the therapeutic agent against degradation in the stomach and allows it to be released in the small intestine or colon. The nanoparticle formulation is particularly effective at protecting sensitive biotherapeutic agents from degradation when administered orally, and makes it possible to avoid administration of such agents by injection. Also provided are methods for producing the formulations, as well as methods of treating diseases employing the formulations.

Abstract: The present invention provides a formulation having excellent solubility and/or stability of a macromolecular drug, and more specifically, a pharmaceutical composition containing a macromolecular drug, a dissolution-enhancing and/or stabilizing agent, and an aqueous solvent, wherein the dissolution-enhancing and/or stabilizing agent is at least one selected from the group consisting of (1) proteins, (2) synthetic polymers, (3) sugars or sugar alcohols, (4) inorganic salts, (5) amino acids, (6) phospholipids, (7) aliphatic alcohols, (8) medium-chain fatty acids, and (9) mucopolysaccharides.

Abstract: Provided is a sheet including a base material comprising a biocompatible material and having at least two independent holes, and a bioactive substance, wherein at least one of the independent holes is an independent hole A containing the bioactive substance, wherein at least one of the independent holes is an independent hole B containing no bioactive substance, wherein a maximum diameter of the independent holes is less than 0.2 mm. Also provided is a sheet laminate including sheets laminated with each other, wherein each of the sheets includes a base material comprising a biocompatible material and having at least two independent holes, and a bioactive substance, wherein at least one of the independent holes is an independent hole A containing the bioactive substance, wherein at least one of the independent holes is an independent hole B containing no bioactive substance.

Abstract: Provided herein are topical compositions, and their use in methods of treating pain and related disorders.

Abstract: There is provided pharmaceutical compositions for the treatment of e.g. opioid dependency comprising microparticles of a pharmacologically-effective amount of buprenorphine, or a pharmaceutically-acceptable salt thereof, in associative admixture with particles comprising a weak acid, or particles comprising weakly-acidic buffer forming materials. The composition may further comprise a disintegrant and/or particles of a pharmacologically-effective amount of naloxone, or a pharmaceutically-acceptable salt thereof. The compositions are useful in the treatment of opioid dependency/addiction and/or pain.

Abstract: Provided is a composition, in particular a solid pharmaceutical composition comprising a compound having the formula I as a free base or a salt thereof, and a mixture comprising a vehicle and a non-ionic surfactant in an amount sufficient to achieve solubilization of compound (I), wherein typically the composition is coated with an enteric coating and its use in the treatment of cancer.

Abstract: Improved aqueous herbicidal compositions comprising at least one water-soluble herbicide and a gel forming agent are provided. The compositions are generally characterized as pseudoplastic, elastic and having a relatively high stationary viscosity. The compositions provide enhanced foliar retention and resistance to drying thereby allowing for improved uptake of the herbicide into the plants and/or translocation within the plant in order to more effectively kill the plants at reduced application rates in kilograms of herbicide per hectare, even in the absence of a surfactant. Methods for confined application of the compositions of the invention to control the growth of unwanted plants are also provided.

Abstract: A process of manufacturing sterile topical ophthalmic aqueous nanosuspensions of nanocrystals of fluticasone propionate Form A. The sterile topical ophthalmic nanosuspensions may be used in the treatment of eye inflammation conditions such as blepharitis, posterior blepharitis, Meibomian gland dysfunction and dry eye through topical administration of said nanosuspensions to eyelids, eyelashes and eyelid margin.